Study of DF6215 in Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT06108479. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 Monotherapy and in Combination Therapy in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors
Study identification
- NCT ID
- NCT06108479
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Dragonfly Therapeutics
- Industry
- Enrollment
- 35 participants
Conditions and interventions
Conditions
Interventions
- DF6215 Drug
- KEYTRUDA® Drug
- pembrolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 27, 2023
- Primary completion
- Dec 3, 2025
- Completion
- Dec 3, 2025
- Last update posted
- Mar 17, 2026
2023 – 2025
United States locations
- U.S. sites
- 9
- U.S. states
- 5
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Angeles Clinic and Research Institute - West Los Angeles Office | Los Angeles | California | 90025 | — |
| University of California Irvine Medical Center | Orange | California | 92868 | — |
| University of California San Diego Moores Cancer Center | San Diego | California | 92093 | — |
| Sarcoma Oncology Center | Santa Monica | California | 90403 | — |
| Tampa General Hospital | Tampa | Florida | 33606 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| NYU Langone Health | New York | New York | 10016 | — |
| Lifespan - Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06108479, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 17, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06108479 live on ClinicalTrials.gov.